Jubilant Ingrevia Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,179Cr
- +12.2% YoY
- +12.2% QoQ
- Net profit
- ₹86Cr
- +16.2% YoY
- +83% QoQ
- Margin
- 14%
- 0 pp YoY
- +2 pp QoQ
Guidance rank: #25 of 70 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
The company expects to accelerate growth starting FY27, with sequential revenue and EBITDA growth beginning Q1 FY27 onward. Jubilant Ingrevia aims for at least 20% year-on-year growth in EBITDA for the full year FY27.
From Jubilant Ingrevia Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects to accelerate growth starting FY27, with sequential revenue and EBITDA growth beginning Q1 FY27 onward.
- Specialty Chemicals and Nutrition segments are projected to lead growth, supported by volume recovery and price stability.
- CDMO business is poised for nonlinear growth, targeting 3x to 4x scaling over the Pinnacle Journey, driven by multiple innovative molecules in agro, pharma, and personal care.
- The large agro contract and other multi-year contracts provide visibility for steady or improved volumes, though some customer volume finalizations remain pending due to market volatility.
- Pipeline of 100+ opportunities with Rs. 3,500 crore potential in CDMO, including phased growth (20-25% peak revenue in Year 1, 50-60% in Year 2, 80%+ in Year 3).
- Nutrition business, notably Human Nutrition premixes, expected to grow rapidly post recent acquisition.
2 more points from Jubilant Ingrevia Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Jubilant Ingrevia Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- For FY27, Jubilant Ingrevia plans capex in the range of INR 400 crore to INR 500 crore to support growth.
- The significant portion of capex will be directed towards the Gajraula Multi-purpose Plant (MPP), expected to commence production in Q4 FY27.
- The company has recently capitalized its CDMO plant in March, leading to a reduction in capital work-in-progress.
- Continued investments align with the Pinnacle growth journey and are aimed at fueling expansion in Fine Chemicals, CDMO, Nutrition, and Specialty segments.
2 more points from Jubilant Ingrevia Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Ingrevia Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Jubilant Ingrevia currently has over 100 CDMO opportunities with a potential of approximately Rs. 3,500 crore.
- There are 20+ confirmed molecules and an additional pipeline of 10+ advanced stage molecules with a peak potential of Rs. 1,100 crore.
- The company secured a significant $300 million CDMO contract started shipping in March FY26, which forms a major pillar for growth in the current year.
- The overall CDMO order book is around Rs. 1,500 crore with various projects at different stages of development.
- New molecules are added every quarter; recent additions include 8 new molecules on top of 15 announced previously.
2 more points from Jubilant Ingrevia Ltd's call on order book
Create a free account to keep reading this call
Jubilant Ingrevia Ltd — Quarterly revenue & net profit
Jubilant Ingrevia Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,179 | 1,051 | +12.2% | 1,051 | +12.2% |
| Operating profit (EBITDA) | 163 | 147 | +10.9% | 126 | +29.4% |
| Operating margin | 14% | 14% | 0 pp | 12% | +2 pp |
| Profit before tax | 112 | 102 | +9.8% | 65 | +72.3% |
| Net profit (PAT) | 86 | 74 | +16.2% | 47 | +83% |
| EPS (₹) | 5.43 | 4.65 | +16.8% | 2.94 | +84.7% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.4K Cr, net profit ₹111 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Ingrevia's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Indian Phosphate (Q4 FY26)
H2 FY26 Revenue (Consolidated):** ₹580.25 Cr, up from ₹451.59 Cr in H2 FY25 — a year-on-year increase of ₹128.66 Cr. Key investor presentation takeaways from In
- Paragon Fine (Q4 FY26)
Revenue for H2FY26:** Rs 68.88 Cr, up 7.41% YoY from Rs 64.13 Cr in H2FY25 (Page 22). Key investor presentation takeaways from Paragon Fine's Q4 FY26 investor p
- IVP (Q4 FY26)
Q4 FY26 revenue from operations: ₹164.44 crore . Key investor presentation takeaways from IVP's Q4 FY26 investor presentation — and how it ranks against sector
- Vishnu Chemicals (Q4 FY26)
Q4 FY26 Operating Revenues: ₹450.3 crore, up 14.7% YoY from ₹392.6 crore in Q4 FY25 (Page 5). Key investor presentation takeaways from Vishnu Chemicals Ltd's Q4
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Jubilant Ingrevia Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jubilant Ingrevia Ltd Q4 FY26 results?
The company expects to accelerate growth starting FY27, with sequential revenue and EBITDA growth beginning Q1 FY27 onward. Jubilant Ingrevia aims for at least 20% year-on-year growth in EBITDA for the full year FY27.
What is Jubilant Ingrevia Ltd share price analysis?
Jubilant Ingrevia Ltd currently shows a neutral. The stock trades at a P/E of 36.9 with a market cap of ₹11,738 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Ingrevia Ltd planning capital expenditure?
For FY27, Jubilant Ingrevia plans capex in the range of INR 400 crore to INR 500 crore to support growth.
Keep Jubilant Ingrevia Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
